GlassScriptPhysician profile
Steven S Dobson
NPI 1982794434
$5,501.00
in general payments reported to CMS, 2019-2025
24 companies · $954 in 2025
The $954 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $221 · 2021: $518 · 2022: $736 · 2023: $1,039 · 2024: $866 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,858.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,867.06 | 2019-2025 | Dailies Total1, Clareon, Total30 |
| Oyster Point Pharma, INC. | $458.34 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $443.69 | 2023-2025 | Infuse, Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $410.05 | 2019-2025 | Acuvue |
| Abbvie INC. | $308.69 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Abb Con-Cise Optical Group LLC | $280.47 | 2019 | |
| Mallinckrodt Hospital Products INC. | $243.10 | 2020-2022 | |
| Allergan, INC. | $229.10 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $199.87 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $191.77 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $139.49 | 2021-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $113.81 | 2019 | |
| Lumibird Medical INC. | $96.09 | 2021 | |
| Dompe US, INC. | $90.88 | 2021-2023 | Oxervate |
| Apellis Pharmaceuticals, INC. | $79.26 | 2023 | Syfovre |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $58.20 | 2020 | |
| Sight Sciences, INC. | $55.69 | 2022-2024 | Tearcare System |
| Maculogix, INC. | $49.96 | 2019 | |
| Ani Pharmaceuticals, INC. | $42.19 | 2025 | Purified Cortrophin Gel |
| Coopervision INC. | $40.91 | 2025 | Myday Contact Lens, Clariti Contact Lens |
| Mallinckrodt Enterprises LLC | $35.95 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $32.41 | 2021 | |
| Quidel Corporation | $18.18 | 2022 | |
| Shire North American Group INC | $15.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Dobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.